Reports

Ideas That Generate Results

List of Figures:

Figure 4-1: Global - Population above 60 Years (Billion), 2013 & 2050
Figure 5-1: Global - Renal Cell Carcinoma Drugs Market (Billion US$), 2015-2020
Figure 6-1: Sutent - Global Revenue (Billion US$), 2011-2014
Figure 6-2: Votrient - Global Revenue (Billion US$), 2011-2014
Figure 6-3: Afinitor - Global Revenue (Billion US$), 2011-2014
Figure 6-4: Nexavar - Global Revenue (Billion US$), 2011-2014
Figure 6-5: Inlyta - Global Revenue (Billion US$), 2012-2014
Figure 6-6: Avastin - Global Revenue (Billion US$), 2011-2014
Figure 6-7: Proleukin - Global Revenue (Billion US$), 2012-2014
Figure 6-8: Torisel - Global Revenue (Billion US$), 2012 & 2013
Figure 7-1: Global - Renal Carcinoma Drugs Market by Geographies (%), 2015
Figure 7-2: North America - Renal Cell Carcinoma Drugs Market (Billion US$), 2015-2020
Figure 7-3: Europe - Renal Cell Carcinoma Drugs Market (Billion US$), 2015-2020
Figure 7-4: Asia-Pacific - Renal Cell Carcinoma Drugs Market (Billion US$), 2015-2020
Figure 11-1: Global - Share of Major Players in Renal Cell Carcinoma Drugs Market (%), 2015
Figure 12-1: Pfizer Inc - Breakup of Revenue by Geographies (%), 2014
Figure 12-2: Roche - Breakup of Pharmaceutical Division Revenue by Geographies (%), 2015
Figure 12-3: Novartis - Breakup of Revenue by Geographies (%), 2014
Figure 12-4: GlaxoSmithKline - Breakup of Revenue by Geographies (%), 2014
Figure 12-5: Bayer AG - Breakup of Revenue by Geographies (%), 2014
Figure 12-6: Bristol Myers Squibb - Breakup of Revenue by Geographies (%), 2014
Figure 12-7: Merck & Co., Inc. - Breakup of Revenue by Geographies (%), 2014
Figure 12-8: AstraZeneca - Breakup of Revenue by Geographies (%), 2014
Figure 12-9: Eli Lilly and Company - Breakup of Revenue by Geographies (%), 2014
Figure 12-10: Amgen Inc. - Breakup of Revenue by Geographies (%), 2014

List of Tables:

Table 8-1: Renal Cell Carcinoma Drugs Pipeline
Table 10-1: Mergers & Acquisitions in Renal Cell Carcinoma Drugs Market, 2013-2016
Table 11-1: Global - Major Renal Cell Carcinoma Drugs
Table 12-1: Pfizer Inc - Revenues by Business Segment (Billion US$), 2012, 2013 & 2014
Table 12-2: Pfizer Inc - Commercialized Renal Cell Carcinoma Drugs
Table 12-3: Pfizer Inc - Renal Cell Carcinoma Drugs Pipeline
Table 12-4: Roche - Revenue by Business Segments (Billion US$), 2013,  2014 & 2015
Table 12-5: Roche - Commercialized Renal Cell Carcinoma Drugs
Table 12-6: Roche - Renal Cell Carcinoma Drug in Pipeline
Table 12-7: Novartis - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-8: Novartis - Commercialized Renal Cell Carcinoma Drugs
Table 12-9: Novartis - Renal Cell Carcinoma Drugs Pipeline
Table 12-10: GlaxoSmithKline - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-11: GlaxoSmithKline - Commercialized Renal Cell Carcinoma Drugs
Table 12-12: GlaxoSmithKline - Renal Cell Carcinoma Drugs Pipeline
Table 12-13: Bayer AG - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-14: Bayer AG - Commercialized Renal Cell Carcinoma Drugs
Table 12-15: Bristol Myers Squibb - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-16: Bristol Myers Squibb - Commercialized Renal Cell Carcinoma Drugs
Table 12-17: Bristol Myers Squibb - Renal Cell Carcinoma Drugs Pipeline
Table 12-18: Merck & Co., Inc. - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-19: Merck & Co., Inc. - Renal Cell Carcinoma Drugs Pipeline
Table 12-20: AstraZeneca - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-21: AstraZeneca - Renal Cell Carcinoma Drugs Pipeline
Table 12-22: Eli Lilly & Co. - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-23: Eli Lilly & Co. - Renal Cell Carcinoma Drugs Pipeline
Table 12-24: Amgen Inc. - Revenue by Business Segments (Billion US$), 2012, 2013 & 2014
Table 12-25: Amgen Inc. - Renal Cell Carcinoma Drugs Pipeline